Tonix's TNX-1500 Advances Transplantation Medicine Tonix Pharmaceuticals' TNX-1500, a third-generation CD40L blocker, has shown promising results in reducing organ rejection rates. Phase 1 trials demonstrated its ability to block immune responses effectively, with potential monthly dosing. This innovation could reshape the $5.5 billion transplant drug market, which is projected to grow significantly by 2030.12